A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer

Purpose: Most high-grade serous ovarian cancer (HGSOC) patients develop recurrent disease after first-line treatment, frequently with fatal outcome. This work aims at studying the molecular biology of both primary and recurrent HGSOC. Experimental Design: Gene expression profiles of matched primary and recurrent fresh-frozen tumor tissues from 66 HGSOC patients were obtained by RNA sequencing. Clustering analyses and pairwise comparison of the profiles between matched samples and subsequent functional alignment were used for the identification of molecular characteristics of HGSOC. Results: Both primary and recurrent HGSOC samples presented predominant gene expression differences in their microenvironment, determined by a panel of genes covering all major pathways of immune activation together with a number of genes involved in the remodeling of extracellular matrix and adipose tissues. Stratifying tumor tissues into immune active and silent groups, we further discovered that although some recurrent tumors shared the same immune status as their primary counterparts, others switched the immune status, either from silent to active or active to silent. Interestingly, genes belonging to the B7-CD28 immune checkpoint family, known for their major role as negative regulators of the immune response, were overexpressed in the immune active tumors. Searching for potential tumor antigens, CEACAM21, a member of the carcinoembryonic antigen family, was found to be significantly overexpressed in immune active tissues in comparison with the silent ones. Conclusions: The results illustrate the complexity of the tumor microenvironment in HGSOC and reveal the molecular relationship between primary and recurrent tumors, which have multiple therapeutic implications. Clin Cancer Res; 23(24); 7621–32. ©2017 AACR.

[1]  D. Glass,et al.  TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis , 2017, The Journal of Immunology.

[2]  Ze Lu,et al.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. , 2016, Advanced drug delivery reviews.

[3]  N. Smargiasso,et al.  Determination of the substrate repertoire of ADAMTS2, 3, and 14 significantly broadens their functions and identifies extracellular matrix organization and TGF‐β signaling as primary targets , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Toby C. Cornish,et al.  PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. , 2016, Human pathology.

[5]  C. Denkert,et al.  Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma , 2015, Oncotarget.

[6]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[7]  E. Puré,et al.  Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice* , 2015, The Journal of Biological Chemistry.

[8]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[9]  H. Hollema,et al.  Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer , 2015, Clinical Cancer Research.

[10]  E. Wardelmann,et al.  PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups , 2015, PloS one.

[11]  G. Heinze,et al.  Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. , 2015, Cancer letters.

[12]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[13]  J. Taube,et al.  Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade , 2015, Clinical Cancer Research.

[14]  Yulei N. Wang,et al.  Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer , 2015, Clinical Cancer Research.

[15]  Pornpimol Charoentong,et al.  Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.

[16]  D. Rimm,et al.  Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites , 2015, Clinical Cancer Research.

[17]  Evis Sala,et al.  Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis , 2015, PLoS medicine.

[18]  P. Nederlof,et al.  Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy , 2014, Cancer Immunology Research.

[19]  Z. Trajanoski,et al.  Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer , 2014, Cancer Immunology, Immunotherapy.

[20]  B. Karlan,et al.  A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer , 2013, Clinical Cancer Research.

[21]  Theresia Thalhammer,et al.  Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium , 2013, BMC Cancer.

[22]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[23]  Yongjun Zhao,et al.  Clonal evolution of high‐grade serous ovarian carcinoma from primary to recurrent disease , 2013, The Journal of pathology.

[24]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[25]  R. Zeillinger,et al.  Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium—OVCAD , 2012, International Journal of Gynecologic Cancer.

[26]  Stephan Harbarth,et al.  Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. , 2012, Journal of clinical epidemiology.

[27]  Hélène Salmon,et al.  Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix , 2012, Oncoimmunology.

[28]  D. Bowtell,et al.  The changing view of high-grade serous ovarian cancer. , 2012, Cancer research.

[29]  G. Xiong,et al.  Abstract 2701: RORα suppresses breast tumor progression by inducing cell polarization and inhibiting cell invasion , 2012 .

[30]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[31]  Fiona M. Watt,et al.  Epithelial stem cells, wound healing and cancer , 2012, Nature Reviews Cancer.

[32]  I. Ozerlat.  Screening: Smile, they're taking a SNaPshot of your cancer-causing genes , 2012, Nature Reviews Clinical Oncology.

[33]  M. Villanueva.  Gynecological cancer: Home is where the fat is , 2012, Nature Reviews Clinical Oncology.

[34]  J. Brenton,et al.  Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.

[35]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[36]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[37]  A. Sood,et al.  Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. , 2011, Neoplasia.

[38]  G. Anderson,et al.  Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.

[39]  Thomas J. Hardcastle,et al.  Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma , 2010, Oncogene.

[40]  Dongxia Gao,et al.  Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors , 2009, PloS one.

[41]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[42]  A. Berner,et al.  NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. , 2006, American journal of clinical pathology.

[43]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[45]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[46]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[47]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[48]  R. Johnstone,et al.  A Role for P-Glycoprotein in Regulating Cell Death , 2000, Leukemia & lymphoma.

[49]  B. Fisher.  Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. , 1982, British journal of cancer.

[50]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .